Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention (Q37448352)

20 August 2017

1 reference

title

Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention (English)

1 reference

20 August 2017

1 reference

1 reference

Claudia Stolz

1

1 reference

20 August 2017

Martin Schuler

series ordinal

2

1 reference

20 August 2017

publication date

1 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

50

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

873-885

1 reference

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Isolation and characterization of the B-cell marker CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

The epitope recognized by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary struc

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Tetraspanin functions and associated microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Mice carrying a CD20 gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Mouse CD20 expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Tyrosine kinase activation in the decision between growth, differentiation, and death responses initiated from the B cell antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Regulation of B-cell signal transduction by adaptor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Lipid rafts and B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Calcium signalling and cell-fate choice in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

New insights into the early molecular events underlying B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

In vivo model of follicular lymphoma resistant to rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Death and anti-death: tumour resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Fcgamma receptors as regulators of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgki

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Mechanisms of cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190902878471

10.1080/10428190902878471

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference